AstraZeneca plans to invest $1.5B in Singapore to build a full-process ADC manufacturing facility for targeted cancer treatment by 2029.
AstraZeneca has announced plans to invest $1.5 billion in building a manufacturing facility in Singapore for producing Antibody Drug Conjugates (ADCs). The new facility will be the first to cover the full manufacturing process for ADCs, a type of highly effective and targeted cancer treatment. The project is supported by the Singapore Economic Development Board and is scheduled to be operational by 2029. ADCs deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.
May 20, 2024
18 Articles